← Leaderboards
Paramita M Ghosh
University Of California Davis
$2,429,169
Attributed
$2,429,169
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $258.1K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,429,169 · 3
VA$0 · 3
By mechanism
R01$2,174,165 · 2
R21$255,004 · 1
I01$0 · 2
IS1$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Davis
Same institution · by research overlap
- Thomas W North$10,896,632
- Michael Steven Denison$8,697,356
- Heike Wulff$18,064,160
- Gordon C Douglas$6,344,342
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateRecurrenceTumorAndrogen ReceptorAffectPreventResistancePharmaceutical PreparationsCellsMediatingAndrogen AntagonistsCastrationCancer PatientNuclearCell NucleusAndrogensTumor ProgressionChemotherapyAcetatesCastration Resistant Prostate CancerDrug ResistanceReportingInhibitor/AntagonistAbiraterone
Grant awards (27)
Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer$0
I01 · FY2024 · VA · contact PI
ShEEP Request for the purchase of a research- grade Cell Imaging Multi-mode Reader$0
IS1 · FY2023 · VA · contact PI
Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer$0
I01 · FY2023 · VA · contact PI
Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer$0
I01 · FY2022 · VA · contact PI
Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer$0
I01 · FY2021 · VA · contact PI
Target, Function and Mechanism of LLS30 in Castration Resistant Prostate Cancer$0
I01 · FY2020 · VA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2019 · VA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2018 · VA · contact PI
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc$258,128
R01 · FY2017 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2017 · VA · contact PI
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc$258,128
R01 · FY2016 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2016 · VA · contact PI
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc$258,128
R01 · FY2015 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2015 · VA · contact PI
(PQD-1) Selective pressure of antiandrogens on castration resistant prostate canc$258,128
R01 · FY2014 · CA · contact PI
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate Cancer$214,551
R01 · FY2013 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2013 · VA · contact PI
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate Cancer$228,246
R01 · FY2012 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2012 · VA · contact PI
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate Cancer$228,246
R01 · FY2011 · CA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2011 · VA · contact PI
Loss of Filamin A Nuclear Localization in Prostate Cancer Progression$0
I01 · FY2011 · VA · contact PI
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate Cancer$235,305
R01 · FY2010 · CA · contact PI
Rapamycin Regulation of the Androgen Receptor: Implications in Prostate Cancer$235,305
R01 · FY2009 · CA · contact PI
Role of HER3 in androgen-independent prostate cancer$18,900
R21 · FY2007 · CA · contact PI
Role of HER3 in androgen-independent prostate cancer$105,814
R21 · FY2006 · CA · contact PI
Role of HER3 in androgen-independent prostate cancer$130,290
R21 · FY2005 · CA